{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:58:28Z","timestamp":1788260308126,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T00:00:00Z","timestamp":1699056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T00:00:00Z","timestamp":1699056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-023-02228-8","type":"journal-article","created":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T06:02:50Z","timestamp":1699077770000},"page":"1289-1294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Endocannabinoid-related molecules predict the metabolic efficacy of GLP-1 receptor agonism in humans with obesity"],"prefix":"10.1007","volume":"47","author":[{"given":"I.","family":"Matias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. W.","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Zizzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Byberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. S.","family":"Torekov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1352-4239","authenticated-orcid":false,"given":"C.","family":"Quarta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,4]]},"reference":[{"key":"2228_CR1","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","volume":"6","author":"RE Pratley","year":"2018","unstructured":"Pratley RE et al (2018) Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 6:275\u2013286","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2228_CR2","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40264-019-00812-7","volume":"42","author":"RM Christensen","year":"2019","unstructured":"Christensen RM, Juhl CR, Torekov SS (2019) Benefit-risk assessment of obesity drugs: focus on glucagon-like peptide-1 receptor agonists. Drug Saf 42:957\u2013971","journal-title":"Drug Saf"},{"key":"2228_CR3","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/obr.12841","volume":"20","author":"E Brown","year":"2019","unstructured":"Brown E, Wilding JPH, Barber TM, Alam U, Cuthbertson DJ (2019) Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: mechanistic possibilities. Obes Rev 20:816\u2013828","journal-title":"Obes Rev"},{"key":"2228_CR4","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","volume":"384","author":"JR Lundgren","year":"2021","unstructured":"Lundgren JR et al (2021) Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med 384:1719\u20131730","journal-title":"N Engl J Med"},{"key":"2228_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1146\/annurev-nutr-043020-090216","volume":"41","author":"SMK Rahman","year":"2021","unstructured":"Rahman SMK, Uyama T, Hussain Z, Ueda N (2021) Roles of endocannabinoids and endocannabinoid-like molecules in energy homeostasis and metabolic regulation: a nutritional perspective. Annu Rev Nutr 41:177\u2013202","journal-title":"Annu Rev Nutr"},{"key":"2228_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.tem.2006.11.006","volume":"18","author":"I Matias","year":"2007","unstructured":"Matias I, Di Marzo V (2007) Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 18:27\u201337","journal-title":"Trends Endocrinol Metab"},{"key":"2228_CR7","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/nrn1247","volume":"4","author":"D Piomelli","year":"2003","unstructured":"Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4:873\u2013884","journal-title":"Nat Rev Neurosci"},{"key":"2228_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.bbi.2022.02.008","volume":"102","author":"A Lama","year":"2022","unstructured":"Lama A et al (2022) Palmitoylethanolamide dampens neuroinflammation and anxiety-like behavior in obese mice. Brain Behav Immun 102:110\u2013123","journal-title":"Brain Behav Immun"},{"key":"2228_CR9","doi-asserted-by":"publisher","first-page":"R595","DOI":"10.1152\/ajpregu.00459.2017","volume":"315","author":"JD Brown","year":"2018","unstructured":"Brown JD et al (2018) Oleoylethanolamide modulates glucagon-like peptide-1 receptor agonist signaling and enhances exendin-4-mediated weight loss in obese mice. Am J Physiol Regul Integr Comp Physiol 315:R595\u2013R608","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2228_CR10","doi-asserted-by":"publisher","first-page":"14302","DOI":"10.1074\/jbc.M115.655662","volume":"290","author":"Y-H Cheng","year":"2015","unstructured":"Cheng Y-H, Ho M-S, Huang W-T, Chou Y-T, King K (2015) Modulation of Glucagon-like Peptide-1 (GLP-1) Potency by Endocannabinoid-like Lipids Represents a Novel Mode of Regulating GLP-1 Receptor Signaling. J Biol Chem 290:14302\u201314313","journal-title":"J Biol Chem"},{"key":"2228_CR11","doi-asserted-by":"publisher","first-page":"E647","DOI":"10.1152\/ajpendo.00146.2020","volume":"319","author":"M Rastelli","year":"2020","unstructured":"Rastelli M et al (2020) Intestinal NAPE-PLD contributes to short-term regulation of food intake via gut-to-brain axis. Am J Physiol Endocrinol Metab 319:E647\u2013E657","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2228_CR12","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.2337\/db08-1237","volume":"58","author":"LM Lauffer","year":"2009","unstructured":"Lauffer LM, Iakoubov R, Brubaker PL (2009) GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 58:1058\u20131066","journal-title":"Diabetes"},{"key":"2228_CR13","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1111\/j.1476-5381.2011.01754.x","volume":"165","author":"H Lan","year":"2012","unstructured":"Lan H et al (2012) Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways. Br J Pharmacol 165:2799\u20132807","journal-title":"Br J Pharmacol"},{"key":"2228_CR14","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s42255-022-00617-6","volume":"4","author":"C Quarta","year":"2022","unstructured":"Quarta C et al (2022) GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice. Nat Metab 4:1071\u20131083","journal-title":"Nat Metab"},{"key":"2228_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.molmet.2018.06.002","volume":"14","author":"F Fanelli","year":"2018","unstructured":"Fanelli F et al (2018) Profiling plasma N-acylethanolamine levels and their ratios as a biomarker of obesity and dysmetabolism. Mol Metab 14:82\u201394","journal-title":"Mol Metab"},{"key":"2228_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1159\/000524753","volume":"107","author":"L Lin","year":"2022","unstructured":"Lin L et al (2022) Diet-induced obesity disrupts histamine-dependent oleoylethanolamide signaling in the mouse liver. Pharmacology 107:423\u2013432","journal-title":"Pharmacology"},{"key":"2228_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.plipres.2022.101194","volume":"89","author":"ED Mock","year":"2023","unstructured":"Mock ED, Gagestein B, van der Stelt M (2023) Anandamide and other N-acylethanolamines: a class of signaling lipids with therapeutic opportunities. Prog Lipid Res 89:101194","journal-title":"Prog Lipid Res"},{"key":"2228_CR18","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/ijo.2014.177","volume":"39","author":"EW Iepsen","year":"2015","unstructured":"Iepsen EW et al (2015) Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss. Int J Obes (Lond) 39:834\u2013841","journal-title":"Int J Obes (Lond)"},{"key":"2228_CR19","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/ijo.2011.165","volume":"36","author":"B Gatta-Cherifi","year":"2012","unstructured":"Gatta-Cherifi B et al (2012) Simultaneous postprandial deregulation of the orexigenic endocannabinoid anandamide and the anorexigenic peptide YY in obesity. Int J Obes (Lond) 36:880\u2013885","journal-title":"Int J Obes (Lond)"},{"key":"2228_CR20","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2337\/db20-0162","volume":"70","author":"P Zizzari","year":"2021","unstructured":"Zizzari P et al (2021) CB1 and GLP-1 receptors cross talk provides new therapies for obesity. Diabetes 70:415\u2013422","journal-title":"Diabetes"},{"key":"2228_CR21","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1530\/EJE-09-0643","volume":"161","author":"V Di Marzo","year":"2009","unstructured":"Di Marzo V et al (2009) Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol 161:715\u2013722","journal-title":"Eur J Endocrinol"},{"key":"2228_CR22","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/cvr\/cvr245","volume":"92","author":"L Ma","year":"2011","unstructured":"Ma L et al (2011) Activation of TRPV1 reduces vascular lipid accumulation and attenuates atherosclerosis. Cardiovasc Res 92:504\u2013513","journal-title":"Cardiovasc Res"},{"key":"2228_CR23","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/hep.31290","volume":"73","author":"MF Fondevila","year":"2021","unstructured":"Fondevila MF et al (2021) The l-\u03b1-lysophosphatidylinositol\/G protein-coupled receptor 55 system induces the development of nonalcoholic steatosis and steatohepatitis. Hepatology 73:606\u2013624","journal-title":"Hepatology"},{"key":"2228_CR24","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1210\/en.2013-1823","volume":"155","author":"G Mattace Raso","year":"2014","unstructured":"Mattace Raso G et al (2014) Palmitoylethanolamide prevents metabolic alterations and restores leptin sensitivity in ovariectomized rats. Endocrinology 155:1291\u20131301","journal-title":"Endocrinology"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02228-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-023-02228-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02228-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T07:20:43Z","timestamp":1713770443000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-023-02228-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,4]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["2228"],"URL":"https:\/\/doi.org\/10.1007\/s40618-023-02228-8","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,4]]},"assertion":[{"value":"21 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SST has received research grants and speaker fees from Novo Nordisk. EWL is employed at Novo Nordisk A\/S, but not at the time of preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the ethical committee in Copenhagen (reference number: H-4-2010-134) and was performed in accordance with the Helsinki Declaration II and with ICH-GCP practice.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Participation in the investigation was voluntary and the individuals could at any time retract their consent to participate. ClinicalTrials.gov Identifier: NCT02094183.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}